Reolysin: Additional Phase II data

Additional data from the open-label, U.S. Phase II REO 016 trial in 36 evaluable patients with metastatic or recurrent K-Ras or EGFR-activated stage IV NSCLC showed that Reolysin plus paclitaxel and carboplatin led to an ORR of 30%, including 11 partial responses plus 21 cases of stable disease. Additionally, Reolysin plus paclitaxel and carboplatin led to a 6-month PFS rate of 38% and a 1-year OS rate of 56%. Patients received IV Reolysin on days 1-5 plus paclitaxel and carboplatin on day 1 of a 21-day cycle. Data were presented at the World Conference on Lung Cancer in Sydney. ...